Pharmacogenomics (PGx) has emerged as a robust, cost-savings, and improvement strategy for employers, payers, providers and patients. What\u2019s more, when implemented across an entire healthcare system, the outcome will be particularly effective. PGx testing provides meaningful data that can help prevent adverse drug reactions, deliver treatments faster, and lower costs.<\/p>\n
By lowering high drug spending and adverse side effects, PGx helps healthcare systems avoid downstream ER visits, hospitalizations, and healthcare errors, which translates into substantial improvements in operational, patient care, and cost efficiencies.<\/p>\n
During this webinar, Dr. Jeffrey Shaman, Chief Science Officer at Coriell Life Sciences (CLS) shares how pharmacogenomics can enhance current wellness and medication risk management programs. Attendees will learn important factors to consider when implementing a pharmacogenomics program across a large population of members as will prescribing physicians who are uninformed on the practice of genetics for personalized prescribing.<\/p>\n